News
2h
Zacks.com on MSNAstrazeneca (AZN) Outpaces Stock Market Gains: What You Should KnowThe most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse ...
AstraZeneca (LSE:AZN) recently entered into a collaborative research initiative with IonQ, AWS, and NVIDIA, focused on ...
1don MSN
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.
Astrazeneca unveiled an ambitious overhaul of its manufacturing and supply operations driven by deep tech, AI, and what it ...
AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.
Explore more
Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...
The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...
1d
Pharmaceutical Technology on MSNEC approves AstraZeneca’s acalabrutinib combo for CLLThe EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.
Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results